Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2021-2030

  Bueno de Mesquita, J M ^a   Sonke, G S ^a   van de Vijver, M J ^a,b   Linn, S C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

70 gene prognosis signature; Adjuvant systemic treatment; Breast cancer; Gene expression profile; Microarray

Indexed keywords

ESTROGEN RECEPTOR;

70 GENE PROGNOSIS SIGNATURE; ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER TISSUE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 80052418906     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp547     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687-1717.
2. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871): 530-536.
3. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347(25): 1999-2009.
4. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98(17): 1183-1192.
5. Bueno-de-Mesquita JM, Linn SC, Keijzer R et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009; 117(3): 483-495.
6. Glas AM, Floore A, Delahaye LJ et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278.
7. Bueno-de-Mesquita JM, van Harten WH, Retel VP et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8(12): 1079-1087.
8. Bogaerts J, Cardoso F, Buyse M et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3(10): 540-551.
9. Cardoso F, van't Veer LJ, Rutgers E et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26(5): 729-735.
10. Creighton CJ, Osborne CK, van de Vijver MJ et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2008; 114(2): 287-299.
11. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16(10): 1569-1583.
12. Todd JH, Dowle C, Williams MR et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987; 56(4): 489-492.
13. D'Eredita' G, Giardina C, Martellotta M et al. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a longterm follow-up that were treated in a single institution. Eur J Cancer 2001; 37(5): 591-596.
14. Kattan MW, Giri D, Panageas KS et al. A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer 2004; 101(11): 2509-2515.
15. Blamey RW, Ellis IO, Pinder SE et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007; 43(10): 1548-1555.
16. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23(12): 2716-2725.
17. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19(4): 980-991.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-481.
19. Cox DR. Regression models and lifetables. J R Stat Soc B 1972; 34: 187-220.
20. Pusztai L, Hatzis C, Cardoso F et al. Combined use of genomic prognostic and treatment response predictors in breast cancer. J Clin Oncol 2009; 26 (Suppl): (Abstr 527).
21. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817-2826.
22. Esteva FJ, Sahin AA, Cristofanilli M et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 11(9): 3315-3319.
23. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26(5): 721-728.
24. Bueno-de-Mesquita JM, Nuyten DSA, Wesseling J et al. The impact of interobserver variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 2010; 21: 40-47.